SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning revenue recognition and internal controls [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Maravai and its executives made false or misleading statements and failed to disclose inadequate internal controls over financial reporting related to revenue recognition [4]. - Maravai identified an error in revenue recognition that resulted in approximately $3.9 million being recorded incorrectly, leading to a material weakness in its internal controls [5]. - Following the announcement of these issues, Maravai's share price fell by$0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [6]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses between August 7, 2024, and February 24, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - There is a deadline of May 5, 2025, for investors to seek the role of lead plaintiff in the federal securities class action filed against Maravai [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will direct and oversee the litigation on behalf of the class [7].